CRISPR Therapeutics’ (CRSP) “Market Outperform” Rating Reiterated at Citizens Jmp

Citizens Jmp restated their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Tuesday,Benzinga reports. Citizens Jmp currently has a $80.00 price objective on the stock.

A number of other brokerages have also weighed in on CRSP. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the stock an “equal weight” rating in a research note on Thursday, June 11th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Sanford C. Bernstein boosted their price objective on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, July 8th. Finally, UBS Group set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $68.06.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $59.37 on Tuesday. The company has a 50 day moving average of $53.55 and a 200 day moving average of $52.67. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. The stock has a market cap of $5.74 billion, a P/E ratio of -12.47 and a beta of 1.74. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The firm had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. As a group, sell-side analysts forecast that CRISPR Therapeutics will post -4.47 EPS for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada raised its position in CRISPR Therapeutics by 28.2% in the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after purchasing an additional 31,392 shares during the period. AQR Capital Management LLC purchased a new stake in CRISPR Therapeutics during the first quarter valued at about $861,000. Woodline Partners LP boosted its position in CRISPR Therapeutics by 34.3% during the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after buying an additional 34,883 shares during the period. Prudential Financial Inc. bought a new position in shares of CRISPR Therapeutics during the second quarter valued at about $237,000. Finally, Invesco Ltd. grew its stake in shares of CRISPR Therapeutics by 138.4% during the second quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock valued at $3,242,000 after buying an additional 38,691 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.